At one point today Incyte stock wasn't far from their one year low. I'm sure that's not what management had in mind for the week that the FDA accepted the NDA for ruxolitinib with a six month priority review. That's a far cry from prices over 20 that… More
Incyte is at an eight year high less than a year after what I believe was a fifteen year low last April. Kudos to anyone who had the foresight or at least the testicles to buy biotech during the meltdown last spring. But if you invested in Incyte… More